Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - a cross-sectional study in six EU member states
ID
Buhl, Caroline
(
Avtor
),
ID
Jacobsen, Ramune
(
Avtor
),
ID
Birna Almarsdóttir, Anna
(
Avtor
),
ID
Abtahi, Shahab
(
Avtor
),
ID
Andersen, Armin
(
Avtor
),
ID
Deligianni, Elena
(
Avtor
),
ID
Dermiki-Gkana, Foteini
(
Avtor
),
ID
Kontogiorgis, Christos
(
Avtor
),
ID
Kos, Mitja
(
Avtor
),
ID
Čebron Lipovec, Nanča
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(608,88 KB)
MD5: 9A34A9FED40E864D4C017E993A7B8028
URL - Izvorni URL, za dostop obiščite
https://www.sciencedirect.com/science/article/pii/S0264410X23015116
Galerija slik
Izvleček
Objective: In 2021, thrombosis with thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines Vaxzevria® and Jcovden®. This study aimed to describe the public’s knowledge of TTS and how it affected the willingness to be vaccinated with COVID-19 vaccines and other vaccines in six European countries. Methods: From June to October of 2022, a multi-country cross-sectional online survey was conducted in Denmark, Greece, Latvia, Netherlands, Portugal, and Slovenia. The minimum target of participants to be recruited was based on the size of the country’s population. The results were analysed descriptively. Results: In total, 3794 respondents were included in the analysis; across the six countries, 33.3 %–68.3 % reported being familiar with signs and symptoms of TTS, although 3.1–61.4 % of those were able to identify the symptoms correctly. The reported changes in willingness to be vaccinated against COVID-19 and with other vaccines varied per country. The largest reported change in the willingness to be vaccinated with Vaxzevria® and Jcovden® was observed in Denmark (61.2 %), while the willingness to be vaccinated with other COVID-19 vaccines changed most in Slovenia (30.4 %). The smallest decrease in willingness towards future vaccination against COVID-19 was reported in the Netherlands (20.9 %) contrasting with the largest decrease observed in Latvia (69.1 %). Conclusion: Knowledge about TTS seemed to have influenced the public’s opinion in Europe resulting in less willingness to be vaccinated with Vaxzevria® and Jcovden®. Willingness for vaccination against COVID-19 with other vaccines and widespread use of vaccines to prevent other diseases also differed and seemed to be determined by the approaches taken by national health authorities when reacting to and communicating about COVID-19 vaccination risks. Further investigation of optimal risk communication strategies is warranted.
Jezik:
Angleški jezik
Ključne besede:
public perception
,
COVID-19 vaccines
,
thrombosis with thrombocytopaenia syndrome (TTS)
,
SARS-CoV-2 adenovirus vector vaccines
,
national health policies
,
risk awareness
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FFA - Fakulteta za farmacijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
Str. 556-563
Številčenje:
Vol. 42, iss. 3
PID:
20.500.12556/RUL-159520
UDK:
614:616.98:578.834
ISSN pri članku:
0264-410X
DOI:
10.1016/j.vaccine.2023.12.065
COBISS.SI-ID:
179573763
Datum objave v RUL:
11.07.2024
Število ogledov:
125
Število prenosov:
30
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Vaccine
Skrajšan naslov:
Vaccine
Založnik:
Butterworth Scientific
ISSN:
0264-410X
COBISS.SI-ID:
26585600
Licence
Licenca:
CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:
Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
javno dojemanje cepiva proti COVID-19
,
tromboza s sindromom trombocitopenije (TTS)
,
vektor adenovirusa SARS-CoV-2
,
nacionalna zdravstvena politika
,
zavedanje o tveganju
,
SARS-CoV-2
,
cepiva
,
COVID-19
,
javno zdravstvo
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
European Medicines Agency
Številka projekta:
EMA/2018/23/PE
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj